Placebo News and Research

RSS

First report of androgen-dependence of exercise on nerve regeneration

A study by researchers from Emory University and Indiana University found that the beneficial effects daily exercise can have on the regeneration of nerves also require androgens such as testosterone in both males and females. It is the first report of both androgen-dependence of exercise on nerve regeneration and of an androgenic effect of exercise in females.

16 Oct 2012

VeriStrat identifies NSCLC patients likely to respond to erlotinib

A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.

16 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Merck, known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection in transplant recipients.

15 Oct 2012

No link between folic acid, vitamin B6 and 12 and increased risk of colorectal adenoma

Combined folic acid, vitamin B6 and vitamin B12 supplements had no statistically significant effect on the risk of colorectal adenoma among women who were at high risk for cardiovascular disease, according to a study published October 12 in the Journal of the National Cancer Institute.

15 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012

Lenalidomide worsens survival, adverse events in prostate cancer

A combination of lenalidomide plus docetaxel and prednisone treatment in patients with chemotherapy-naive prostate cancer leads to worse overall survival rates and increased toxicity compared with placebo, show study results.

12 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Two CUMC studies provide new insights into spinal muscular atrophy

A study by scientists from the Motor Neuron Center at Columbia University Medical Center (CUMC) suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought.

12 Oct 2012

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

12 Oct 2012

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Timothy Henry, M.D. of the Minneapolis Heart Institute Foundation treated the first patient in the ATHENA study, injecting the patient's own stem cells into the heart to restore blood flow and help regenerate heart muscle. Henry, the Foundation's Director of Research is co-principal investigator of the ATHENA study sponsored by Cytori Therapeutics.

12 Oct 2012

Heart drug could ease rare muscle disorder

The anti-arrhythmic drug mexiletine may improve symptoms in patients with nondystrophic myotonias, shows a small randomized trial published in JAMA.

11 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

Placebo News and Research

First report of androgen-dependence of exercise on nerve regeneration

VeriStrat identifies NSCLC patients likely to respond to erlotinib

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Merck, AiCuris enter licensing agreement for novel HCMV candidates

No link between folic acid, vitamin B6 and 12 and increased risk of colorectal adenoma

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Lenalidomide worsens survival, adverse events in prostate cancer

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Two CUMC studies provide new insights into spinal muscular atrophy

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Heart drug could ease rare muscle disorder

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Testosterone fosters social behavior in men

Zero out of TEN for fecal incontinence treatment

HVLA manipulation comes out top for low-back pain

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News